



DRIVING INNOVATION



Delivering Affordability



H1 FY 2009-10  
October 22 , 2009



# DISCLAIMER



Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our company, nor our directors, nor any of their respective affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.



# Business Operations



**2QFY10 Syngene and Clinigene performance- have posted excellent strong results**

**Biocon's acquires Hyderabad-based bulk manufacturer IDL Specialty for API opportunities. Plans to expand chemical synthesis capabilities to manufacture advanced intermediates**



# Business Operations



**Biocon's pact with Amylin for peptide therapeutics is in support of potential treatment of diabetes . Research would center on Amylin's "phybrid" technology.**

**German subsidiary AxiCorp's performance – Robust & profitable. The regulatory process for the registration of Recombinant Human Insulin with EMEA on track .**



## INNOVATION PROGRESS

Oral Insulin program, IN 105, expects to complete patient enrollment in Q3 this fiscal.

IN 105 - expects to report Phase III data by the end of Q1/Q2 FY2011.



# Business Outlook



## INNOVATION PLAN

**Oral insulin is a global blockbuster market opportunity**

**Based on the outcome of the Phase III trials, we will pursue a go-to-market strategy of launching in India first.**

**We expect to realize a large licensing opportunity for Biocon with this molecule.**



# Business Operations



**T1h, - promising Phase II data in Rheumatoid Arthritis (RA) as well as Psoriasis.**

**Phase III trials for Psoriasis by the end of this calendar year and Phase III for RA in the next calendar year.**

**Partnership with Mylan for Bio-similars is on track, larger returns are expected post 2014 once the regulated markets open up.**



## INNOVATION PLAN

**T1h will shortly enter phase III trials for Psoriasis we expect to initiate licensing discussions for this over the next 12 months.**


**Phase III for Rheumatoid Arthritis will commence in the next calendar year.**

**With respect to our immuno-conjugates program with IATRICa, we expect to file the IND by Q2 FY2011.**





T1h: 0.8 mg/kg once every 4 weeks



Day 1



Day 29

Day 57





T1h: 0.4mg/kg once every 4 weeks



**Day 1**

**Day 29**





T1h: 0.4mg/kg once every 4 weeks



Day 1



Day 29





T1h: 0.8 mg/kg once every 4 weeks



Day 1



Day 29





**Forecast strong organic growth going forward , open to inorganic growth opportunities when they present themselves at the right price**



# Biologics & Biogenerics: A large opportunity



**Present Biologics market:**

**US Market: \$60 billion**

**EU Market: \$30 billion**

**ROW Markets: \$5 billion**

**\$25 billion worth of biologics are  
losing patent protection by 2016.  
Forecast 2020 – 7 of 10 top selling  
drugs will be Biologics.**



## COLLABORATION WITH MYLAN TO COMMERCIALIZE BIO-GENERICS

Through a profit-sharing model.

This will advance our efforts to secure a leading position in the emerging industry.





**Syngene received its official accreditation by The AAALAC International (the Association for Assessment and Accreditation of Laboratory Animal Care International).**





**Kiran Mazumdar Shaw :**

**Among world's 100 most powerful women was featured in the prestigious ranking by Forbes. This year, only 3 Indians are featured in the list.**

**Included in the prestigious 'Top 50 Women In Business' listing by Financial Times, London.**



**CORPORATE DEVELOPMENTS**



**Biocon Among 20 Indian Companies In Forbes 'Best Under A Billion'**


**Biocon 'Best under A  
Billion' - listing by  
Forbes.**



# SALES HIGHLIGHTS



Rs.Crores





## FINANCIAL HIGHLIGHTS



Rs.Crores


	H1 FY10	As a % of Total Revenue	H1 FY09	As a % of Total Revenue
<b>Revenues</b>	1,098		734	
<b>EBIDTA</b>	236	22%	168	23%
<b>PBT</b>	158	14%	106	15%
<b>PAT (Before Exceptional)</b>	132	12%	100	14%
<b>PAT (After Fx MTM)</b>	132	12%	40	5%



# Financial Performance – YoY Growth

## H1 FY2010 vs. H1 FY2009

(Rs Crores)





**THANK YOU**

